Abstract:Objective: Despite modern therapies, pulmonary arterial hypertension (PAH) harbors a high mortality. Vascular remodeling is a hallmark of the disease. Recent clinical studies revealed that antiremodeling approaches with tyrosine-kinase inhibitors such as imatinib are effective, but its applicability is limited by significant side effects. Although imatinib has multiple targets, expression analyses support a role for platelet-derived growth factor (PDGF) in the pathobiology of the disease. However, its precise role and downstream signaling events have not been established. Approach and results: Patients with PAH exhibit enhanced expression and phosphorylation of β PDGF receptor (βPDGFR) in remodeled pulmonary arterioles, particularly at the binding sites for phophatidyl-inositol-3-kinase and PLCγ at tyrosine residues 751 and 1021, respectively. These signaling molecules were identified as critical downstream mediators of βPDGFR-mediated proliferation and migration of pulmonary arterial smooth muscle cells. We, therefore, investigated mice expressing a mutated βPDGFR that is unable to recruit phophatidyl-inositol-3-kinase and PLCγ (βPDGFR(F3/F3)). PDGF-dependent Erk1/2 and Akt phosphorylation, cyclin D1 induction, and proliferation, migration, and protection against apoptosis were abolished in βPDGFR(F3/F3) pulmonary arterial smooth muscle cells. On exposure to chronic hypoxia, vascular remodeling of pulmonary arteries was blunted in βPDGFR(F3/F3) mice compared with wild-type littermates. These alterations led to protection from hypoxia-induced PAH and right ventricular hypertrophy. Conclusions: By means of a genetic approach, our data provide definite evidence that the activated βPDGFR is a key contributor to pulmonary vascular remodeling and PAH. Selective disruption of PDGF-dependent phophatidyl-inositol-3-kinase and PLCγ activity is sufficient to abolish these pathogenic responses in vivo, identifying these signaling events as valuable targets for antiremodeling strategies in PAH.

The Structural and Functional Studies of the PDGF Receptors

Clinical development of dual tyrosine kinase inhibitors targeting vascular endothelial growth factor receptor and platelet- derived growth factor receptor

Current status of drugs targeting PDGF/PDGFR

Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review

Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis

Roles of platelet-derived growth factor and platelet-derived growth factor receptors in cardiovascular diseases

Role and mechanism of platelet-derived growth factor in cell proliferation and tissue repair

Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers

Emerging Roles of PDGF-D in EMT Progression During Tumorigenesis.

Research progress on the role of PDGF/PDGFR in type 2 diabetes

PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics

Structures of a Platelet-Derived Growth Factor/propeptide Complex and a Platelet-Derived Growth Factor/receptor Complex.

Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role

[Research Advances of Platelet Derived Growth Factor Family and Its Significance in Neovascular Eye Diseases].

Phospholipase D as a key modulator of cancer progression

Expression of Platelet-Derived Growth Factor-Bb in Liver Tissues of Patients with Chronic Hepatitis B.

Two Platelet-derived Growth Factor Receptors in Vascular Smooth Muscle Cells.

PDGF Promotes the Warburg Effect in Pulmonary Arterial Smooth Muscle Cells via Activation of the PI3K/AKT/mTOR/HIF-1α Signaling Pathway

Regulatory Effect of PDGF/PDGFR on Hematopoiesis

Screening and Analysis of Possible Drugs Binding to PDGFRα: A Molecular Modeling Study

Genetic Ablation of PDGF-Dependent Signaling Pathways Abolishes Vascular Remodeling and Experimental Pulmonary Hypertension